

# Pentoxifylline Extended Release Tablets

The extended release tablet contains **Pentoxifylline 400 mg**. This formulation features use of **Carbopol® 71G NF** and **Carbopol® 971P NF polymer** as the extended release matrix ingredients. The formulation has high drug loading of 66.67% and meets the USP drug dissolution requirements (Test 1).

Number	Ingredients	% w/w	mg / Tablet
<b>Intra-Granular Phase:</b>			
1.	Pentoxifylline	66.67	400.00
2.	<b>Carbopol® 971P NF polymer</b>	5.00	30.00
3.	Silicon dioxide	0.50	3.0
<b>Extra-Granular Phase:</b>			
4.	<b>Carbopol® 71G NF Polymer</b>	15.00	90.00
5.	Microcrystalline cellulose (Microcel® PH102)	11.83	71.00
6.	Glyceryl behenate (Compritol® 888 ATO)	1.00	6.00
<b>TOTAL:</b>		<b>100.00</b>	<b>600.00</b>

Lab batch size - 1000 g (Ethanol : water 1:1 mixture used as binding liquid).

## Process:

1. Pass pentoxifylline, **Carbopol® 971P NF polymer** and silicon dioxide through 20 mesh screen. Add the ingredients to high shear mixer and blend for 10 minutes at 150 rpm.
2. Granulate the blend with 1:1 mixture of ethyl alcohol and water in high shear granulator, using about 50 g mixture for 1kg powder blend adding the mixture as a thin stream, as droplets using peristaltic pump or as a spray and impeller speed above 250 to 300 rpm during wet massing.
3. Dry the granules in fluid bed drier (inlet temperature at 45 °C) to loss on drying (LOD) of about 2%.
4. Pass the dry granules through 20 mesh screen and blend them with microcrystalline cellulose PH102, Carbopol® 71G NF polymer and Compritol 888 ATO in a V-blender for 15 minutes at 25 rpm.
5. Compress the blend into tablets on a tablet press as follows:
  - Punches: 18 x 7 mm standard convex caplet shape
  - Target weight: 600 mg
  - Mechanical strength: minimum 10 kP
  - Friability: NMT 1.0 % w/w (100 revolutions)

# Pentoxifylline Extended Release Tablets

Final Tablet Properties:
<b>Appearance:</b> Biconvex, caplet shaped tablets
<b>Weight (mg)*:</b> 606 ± 4.5
<b>Thickness (mm)*:</b> 5.23 ± 0.04
<b>Mechanical Strength (kP)*:</b> 22 ± 1.3
<b>Friability (100 revolutions) (%):</b> 0.13

Dissolution**(% average of 6 tablets)		
Time (h)	Lubrizol	USP Limits
1	9.91%	NMT 30%
4	36.66%	30-55%
8	66.99%	NLT 60%
12	91.33%	NLT 80%

\*Average ± SD

\*\*Dissolution method per USP monograph of Pentoxifylline ER tablets (Test 1). USP Apparatus 2, 100 RPM, 900 ml water.

## Summary:

Carbopol® polymers have demonstrated to be useful and highly efficient as extended release matrix former making them a polymer of choice when formulating high drug load extended release tablets.

The Lubrizol Life Science Health website [www.lubrizol.com/Health](http://www.lubrizol.com/Health) provides additional information:

- Bulletin 30 - Controlled Release Tablets and Capsules; Bulletin 31 - Formulating Controlled Release Tablets and Capsules with Carbopol; Bulletin 32 - Application of Carbopol 71G NF Polymer in Controlled Release Tablets
- Aqueous and non- aqueous granulation videos under video gallery
- Technical Papers, Technical Data Sheets, Test Procedures, Certificates, and other Formulations

**Please contact your Lubrizol representative to get samples, quotations or further technical assistance.**

